JP5600294B2 - 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品 - Google Patents

治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品 Download PDF

Info

Publication number
JP5600294B2
JP5600294B2 JP2010524134A JP2010524134A JP5600294B2 JP 5600294 B2 JP5600294 B2 JP 5600294B2 JP 2010524134 A JP2010524134 A JP 2010524134A JP 2010524134 A JP2010524134 A JP 2010524134A JP 5600294 B2 JP5600294 B2 JP 5600294B2
Authority
JP
Japan
Prior art keywords
cells
composition
therapeutic
cell
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010524134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539084A5 (https=
JP2010539084A (ja
Inventor
ウィリアム エイチ． ザ セカンド フレイ，
ルージーン ダニエリアン，
クリストフ ハー． グレイター，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010539084A publication Critical patent/JP2010539084A/ja
Publication of JP2010539084A5 publication Critical patent/JP2010539084A5/ja
Application granted granted Critical
Publication of JP5600294B2 publication Critical patent/JP5600294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
JP2010524134A 2007-09-11 2008-09-04 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品 Active JP5600294B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US60/971,284 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US12/109,066 2008-04-24
PCT/US2008/075223 WO2009035901A1 (en) 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014040359A Division JP2014098051A (ja) 2007-09-11 2014-03-03 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品

Publications (3)

Publication Number Publication Date
JP2010539084A JP2010539084A (ja) 2010-12-16
JP2010539084A5 JP2010539084A5 (https=) 2012-10-04
JP5600294B2 true JP5600294B2 (ja) 2014-10-01

Family

ID=40432083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010524134A Active JP5600294B2 (ja) 2007-09-11 2008-09-04 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品
JP2014040359A Withdrawn JP2014098051A (ja) 2007-09-11 2014-03-03 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014040359A Withdrawn JP2014098051A (ja) 2007-09-11 2014-03-03 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品

Country Status (24)

Country Link
US (3) US8283160B2 (https=)
EP (1) EP2200621B1 (https=)
JP (2) JP5600294B2 (https=)
KR (2) KR101504110B1 (https=)
CN (2) CN101801397A (https=)
AT (1) ATE554778T1 (https=)
AU (1) AU2008299124B2 (https=)
BR (1) BRPI0816325B8 (https=)
CA (1) CA2696892C (https=)
CR (1) CR11304A (https=)
CY (1) CY1113120T1 (https=)
DK (1) DK2200621T3 (https=)
ES (1) ES2388403T3 (https=)
HR (1) HRP20120560T1 (https=)
IL (1) IL204371A (https=)
MX (1) MX2010002738A (https=)
MY (1) MY154061A (https=)
PL (1) PL2200621T3 (https=)
PT (1) PT2200621E (https=)
RU (1) RU2468818C2 (https=)
SG (1) SG184724A1 (https=)
SI (1) SI2200621T1 (https=)
UA (1) UA98507C2 (https=)
WO (1) WO2009035901A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
EP2794854B1 (en) 2011-12-23 2018-06-20 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015134869A2 (en) * 2014-03-06 2015-09-11 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
EP3174584B1 (en) * 2014-07-29 2022-05-04 Edenhoffer, Peter Positive pressure inspiration device for delivery of medicaments
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017011326A1 (en) 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
ES2938089T3 (es) 2015-08-13 2023-04-04 Takeda Pharmaceuticals Co Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
WO2005056755A2 (en) * 2003-12-02 2005-06-23 Catholic Healthcare West Compositions and methods for propagation of neural progenitor cells
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
AU2008299124B2 (en) 2013-07-04
SI2200621T1 (sl) 2012-09-28
MY154061A (en) 2015-04-30
UA98507C2 (ru) 2012-05-25
CY1113120T1 (el) 2016-04-13
CA2696892C (en) 2016-05-17
HRP20120560T1 (hr) 2012-08-31
AU2008299124A1 (en) 2009-03-19
EP2200621B1 (en) 2012-04-25
US9445991B2 (en) 2016-09-20
RU2468818C2 (ru) 2012-12-10
PL2200621T3 (pl) 2012-10-31
ES2388403T3 (es) 2012-10-15
EP2200621A4 (en) 2011-03-16
MX2010002738A (es) 2010-08-04
BRPI0816325B1 (pt) 2020-04-22
WO2009035901A1 (en) 2009-03-19
DK2200621T3 (da) 2012-08-06
US20090068155A1 (en) 2009-03-12
SG184724A1 (en) 2012-10-30
CN101801397A (zh) 2010-08-11
BRPI0816325B8 (pt) 2021-05-25
CA2696892A1 (en) 2009-03-19
US8283160B2 (en) 2012-10-09
US20130028874A1 (en) 2013-01-31
PT2200621E (pt) 2012-07-31
US20160206554A1 (en) 2016-07-21
CN103181932A (zh) 2013-07-03
KR20100094450A (ko) 2010-08-26
CR11304A (es) 2010-05-03
IL204371A (en) 2015-02-26
JP2014098051A (ja) 2014-05-29
BRPI0816325A2 (pt) 2015-03-24
ATE554778T1 (de) 2012-05-15
RU2010113932A (ru) 2011-10-20
KR101504110B1 (ko) 2015-03-19
KR20150039197A (ko) 2015-04-09
JP2010539084A (ja) 2010-12-16
EP2200621A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
JP5600294B2 (ja) 治療用細胞を動物の中枢神経系に投与するための方法、医薬組成物および製品
JP2010539084A5 (https=)
Thanos et al. Survival and axonal elongation of adult rat retinal ganglion cells: in vitro effects of lesioned sciatic nerve and brain derived neurotrophic factor
US20020169102A1 (en) Intranasal delivery of agents for regulating development of implanted cells in the CNS
Park et al. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
EP2139497A2 (en) Methods for treating nervous system injury and disease
Moore et al. Four steps to optic nerve regeneration
JPWO2002002135A1 (ja) 脱髄疾患の予防及び治療薬
CN103028110B (zh) 抗分泌因子的新用途
US20240012011A1 (en) Methods and assays for secretome activity analysis
Krityakiarana et al. Proof-of concept that an acute trophic factors intervention after spinal cord injury provides an adequate niche for neuroprotection, recruitment of nestin-expressing progenitors and regeneration
HK1182932A (en) Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
WO2000006700A1 (en) Production and use of dopaminergic cells to treat dopaminergic deficiencies
KR20230129828A (ko) 안구 후방 질환 또는 손상의 예방 또는 치료용 조성물
WO2010060928A2 (en) Compositions for the treatment of ischemic tissue damage
Hollis II Intrinsic and extrinsic mechanisms of corticospinal axon regeneration

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140425

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140815

R150 Certificate of patent or registration of utility model

Ref document number: 5600294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250